πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,254 results for β€œFirst” Clear

  1. Jianpi Lishi Jiedu Granules

    First Tracks Biotherapeutics

    Colorectal Adenoma

    phase 3 small molecule active

    1 trial

  2. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion

    Disc Medicine

    Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.

    phase 3 small molecule active

    1 trial

  3. Ketorolac

    First Tracks Biotherapeutics

    Aortic Dissection

    phase 3 small molecule active

    1 trial

  4. Keverprazan Hydrochloride tablets + high dose amoxicillin

    First Tracks Biotherapeutics

    Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education

    phase 3 small molecule active

    1 trial

  5. Lenvatinib

    First Tracks Biotherapeutics

    Hepatocellular Carcinoma

    phase 3 small molecule terminated

    1 trial

  6. Letrozole

    First Tracks Biotherapeutics

    Polycystic Ovary Syndrome

    phase 3 small molecule completed

    1 trial

  7. Megestrol（YiningοΌ‰

    First Tracks Biotherapeutics

    Stage III Esophageal Squamous Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  8. Metformin plus pioglitazone

    First Tracks Biotherapeutics

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  9. Methylprednisolone pulse

    First Tracks Biotherapeutics

    Glomerulonephritis, IGA

    phase 3 small molecule terminated

    1 trial

  10. Methylprednisolone sodium succinate

    First Tracks Biotherapeutics

    Acute Ischemic Stroke

    phase 3 small molecule active

    1 trial

  11. Mimetic granules of Yiqi-Wenjing prescriptions

    First Tracks Biotherapeutics

    Chemotherapy-induced Peripheral Neuropathy

    phase 3 small molecule active

    1 trial

  12. Mitoxantrone Hydrochloride Liposome

    First Tracks Biotherapeutics

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  13. N-Acetylcysteine

    First Tracks Biotherapeutics

    Thrombotic Microangiopathies

    phase 3 small molecule completed

    1 trial

  14. N-Acetylcysteine (NAC) Treatment

    First Tracks Biotherapeutics

    Thrombotic Microangiopathy

    phase 3 small molecule active

    1 trial

  15. Nedaplatin

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma

    phase 3 small molecule completed

    1 trial

  16. Nimotuzumab

    First Tracks Biotherapeutics

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  17. Normal Saline

    First Tracks Biotherapeutics

    Postoperative Sleep Disturbance

    phase 3 small molecule active

    1 trial

  18. Osimertinib

    First Tracks Biotherapeutics

    Non-small Cell Carcinoma

    phase 3 small molecule active

    1 trial

  19. Oxaliplatin

    First Tracks Biotherapeutics

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  20. Oxaliplatin,calcium folinic acid, levofolinic acid, 5-FU

    First Tracks Biotherapeutics

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  21. PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo

    BioNTech Manufacturing GmbH

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  22. PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Cancer Prevention Pharma (Ireland) Limited

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  23. Paclitaxel

    First Tracks Biotherapeutics

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  24. Paclitaxel or docetaxel + Cisplatin or carboplatin

    First Tracks Biotherapeutics

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources